Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictions and related disorders. News about Adial often centers on the progress of its lead investigational drug, AD04, a genetically targeted serotonin-3 receptor antagonist being developed for Alcohol Use Disorder (AUD) in heavy drinking patients with specific genotypes.
On this page, readers can find coverage of Adial’s clinical development milestones, including updates on the ONWARD™ pivotal Phase 3 trial and preparations for a new Phase 3 adaptive program informed by End of Phase 2 (EOP2) feedback from the U.S. Food and Drug Administration (FDA). Company announcements describe FDA recognition of AUD as an unmet need, support for Adial’s adaptive trial design, and confirmation of primary efficacy endpoints based on heavy drinking days.
Adial’s news flow also highlights its precision medicine strategy. Releases describe a partnership with Genomind to validate a cheek swab genetic test that identifies SNPs in serotonergic system genes such as HTR3A, HTR3B, and SLC6A4, enabling selection of biomarker-positive patients, including those with the AG+ genotype. Additional stories cover intellectual property developments, such as provisional and international patent applications for AD04 that the company expects, once granted, to protect core assets to at least 2045.
Investors and observers can also follow capital markets and listing-related updates, including public offerings of stock and warrants, at-the-market sales agreements, Nasdaq compliance notices, and extensions related to minimum bid price requirements. Together, these items provide context on how Adial is financing and structuring its efforts to advance AD04 and its broader addiction treatment pipeline. Bookmark this page to review new regulatory, clinical, financing, and intellectual property announcements as they are reported.
Adial Pharmaceuticals (NASDAQ: ADIL) has been granted a new U.S. patent (No. 12,226,401) on February 18, 2025, expanding its genetic-based approach to treating and diagnosing alcohol use disorder and drug dependencies. The patent covers methods for identifying genetic markers in patients with alcohol or opioid-related disorders.
The patent specifically focuses on identifying genotypes including the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene. This advancement will enable healthcare providers to develop tailored treatment plans using AD04, Adial's investigational drug product. The precision medicine approach aims to optimize treatment outcomes while minimizing risks associated with standardized treatments.
Adial Pharmaceuticals (NASDAQ: ADIL) has been awarded U.S. patent number 12,221,654 on February 11, 2025, expanding its molecular genetic approach to diagnosing and treating addiction disorders. The patent covers methods for identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, the company's investigational drug.
The treatment specifically involves detecting the TT genotype of rs1042173 in the serotonin transporter gene (SLC6A4) and administering AD04 to patients. This approach is designed for treating various conditions including opioid dependence, opioid abuse, and alcohol dependence. The company aims to deliver personalized treatments by combining genetic diagnostics with precision medicine, targeting patients who may not respond to conventional therapies.
Adial Pharmaceuticals (NASDAQ: ADIL) has announced positive results from its AD04-103 pharmacokinetics study for AD04, a drug candidate being developed to treat Alcohol Use Disorder (AUD). The study, involving 30 healthy volunteers across two cohorts, demonstrated predictable bioavailability and dose proportionality in pharmacokinetic exposure.
The study confirmed that ondansetron pharmacokinetic exposure increased proportionally between AD04 0.33 mg tablets and marketed ondansetron 4 mg tablets, with no food effect on administration. These results support Adial's plans to pursue FDA approval under the 505(b)(2) regulatory pathway.
The company has submitted the results to the FDA and plans an End-of-Phase 2 meeting in the first half of the year to discuss the Phase 3 program design. The successful completion of this bridging study is expected to facilitate ongoing partnership discussions.
Adial Pharmaceuticals (NASDAQ: ADIL) has been granted U.S. patent number 12150931 on November 26, 2024, expanding its intellectual property coverage for treating alcohol and drug dependence. The patent covers broader genotype combinations identified by the company's proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, their lead investigational drug. The patent specifically includes HTR3A, HTR3B, and SLC6A4 receptor sites, supporting their precision medicine approach to addiction treatment. This patent protection extends through 2031.
Adial Pharmaceuticals (NASDAQ: ADIL) announced positive topline results from the AD04-103 Pharmacokinetics Study for their alcohol use disorder treatment. The study, involving 30 healthy adult volunteers, confirmed AD04's relative bioavailability to reference ondansetron, demonstrated dose-proportional increases in pharmacokinetic exposure, and showed no food effect. The study met FDA requirements for upcoming Phase 3 trials and will help optimize the study design. Results showed AD04 0.33mg delivered lower ondansetron exposure than the 4mg reference tablet, with proportional increases across a 3-fold dose range. The company plans to engage with FDA in Q4 2024 to discuss Phase 3 study program.
Adial Pharmaceuticals (NASDAQ: ADIL) reported Q3 2024 financial results and business updates. The company achieved database lock for AD04's pharmacokinetics study in Alcohol Use Disorder (AUD) treatment. Cash position stood at $5.2 million as of September 30, 2024, expected to fund operations into H2 2025. Q3 net loss increased to $2.2 million from $1.4 million year-over-year. R&D expenses rose 399% due to clinical trial and CMC costs. The company partnered with Boudicca Dx for companion diagnostic development and secured new patent allowances.
Adial Pharmaceuticals (NASDAQ: ADIL) has appointed Vinay Shah as Chief Financial Officer, effective November 16, 2024. Shah brings over 25 years of experience in pharmaceutical and healthcare sectors, previously serving as CFO at Virpax Pharmaceuticals. His track record includes raising over $150 million at Aravive and contributing to Pacira Pharmaceuticals' IPO. The current CFO, Joseph Truluck, will resign on November 15, 2024, but will continue as a consultant through March 31, 2025, to ensure a smooth transition. Truluck's departure is not related to any disagreements with the company's operations or practices.
Adial Pharmaceuticals (NASDAQ: ADIL) has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. CEO Cary Claiborne will deliver a presentation at 8:30 a.m. ET, and management will conduct one-on-one investor meetings throughout the day. The conference brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies. Investors can register to attend and schedule meetings, with the presentation available via live stream.
Adial Pharmaceuticals (NASDAQ: ADIL) has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent. This patent will expand Adial's intellectual property protection for its lead investigational drug, AD04, designed to treat alcohol use disorder (AUD). The patent covers additional genotype combinations identified through the Company's proprietary genetic diagnostic tool, enhancing AD04's precision medicine approach.
Cary Claiborne, CEO of Adial Pharmaceuticals, stated that this milestone broadens their patent estate and provides greater flexibility in advancing AD04. He emphasized the company's commitment to delivering innovative, genetically-targeted treatments for addiction. The patent notification reinforces Adial's focus on using cutting-edge science to develop more effective treatments with fewer side effects for those affected by addiction.
Adial Pharmaceuticals (NASDAQ: ADIL) commends the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for its updated definition of recovery, which now includes non-abstinence solutions. This aligns with Adial's AD04 program for alcohol use disorder (AUD), which offers patients flexibility in reducing drinking and/or achieving abstinence.
The NIAAA's new definition, emphasized in its 2025 Professional Judgement Budget, recognizes that effective recovery solutions can focus on harm reduction and improved quality of life. This shift validates Adial's approach and potentially broadens its commercial and government market potential.
Cary Claiborne, CEO of Adial Pharmaceuticals, stated that AD04 is uniquely positioned to provide a therapeutic option for those seeking reduction in alcohol use or complete abstinence. The company is optimistic that NIAAA's new perspective will stimulate additional support for programs like AD04 in both commercial and government sectors.